Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CUE BIOPHARMA INC (CUE) Stock Price & Overview
NASDAQ:CUE • US22978P1066
Current stock price
30.42 USD
+15.68 (+106.38%)
At close:
30.78 USD
+0.36 (+1.18%)
After Hours:
The current stock price of CUE is 30.42 USD. Today CUE is up by 106.38%. In the past month the price increased by 463.65%. In the past year, price increased by 34.73%.
CUE Key Statistics
52-Week Range4.971 - 38
Current CUE stock price positioned within its 52-week range.
1-Month Range4.971 - 38
Current CUE stock price positioned within its 1-month range.
- Market Cap
- 2.971B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.31
- Dividend Yield
- N/A
CUE Stock Performance
Today
+106.38%
1 Week
+71.91%
1 Month
+463.65%
3 Months
+202.87%
Longer-term
6 Months +32.10%
1 Year +34.73%
2 Years -37.79%
3 Years -74.65%
5 Years -92.93%
10 Years N/A
CUE Stock Chart
CUE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CUE. When comparing the yearly performance of all stocks, CUE is one of the better performing stocks in the market, outperforming 96.78% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CUE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CUE. While CUE has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CUE Earnings
Next Earnings DateMay 6, 2026
Last Earnings DateMar 24, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise 768.99%
CUE Forecast & Estimates
5 analysts have analysed CUE and the average price target is 122.4 USD. This implies a price increase of 302.37% is expected in the next year compared to the current price of 30.42.
For the next year, analysts expect an EPS growth of -41.46% and a revenue growth -87.5% for CUE
Analysts
Analysts80
Price Target122.4 (302.37%)
EPS Next Y-41.46%
Revenue Next Year-87.5%
CUE Financial Highlights
Over the last trailing twelve months CUE reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 58.19% compared to the year before.
Income Statements
Revenue(TTM)27.47M
Net Income(TTM)-26.60M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.02% | ||
| ROE | -100.64% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%111.52%
Sales Q2Q%1292.26%
EPS 1Y (TTM)58.19%
Revenue 1Y (TTM)195.75%
CUE Ownership
Ownership
Inst Owners22.31%
Shares97.66M
Float97.11M
Ins Owners0.4%
Short Float %N/A
Short Ratio0.66
CUE Industry Overview
CUE operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
CUE Latest News, Press Relases and Analysis
CUE Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CUE
Company Profile
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Company Info
IPO: 2018-01-02
CUE BIOPHARMA INC
40 Guest Street
Boston MASSACHUSETTS 02139 US
CEO: Daniel R. Passeri
Employees: 41
Phone: 16179492680
CUE BIOPHARMA INC / CUE FAQ
What does CUE do?
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Can you provide the latest stock price for CUE BIOPHARMA INC?
The current stock price of CUE is 30.42 USD. The price increased by 106.38% in the last trading session.
Does CUE BIOPHARMA INC pay dividends?
CUE does not pay a dividend.
How is the ChartMill rating for CUE BIOPHARMA INC?
CUE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for CUE stock?
5 analysts have analysed CUE and the average price target is 122.4 USD. This implies a price increase of 302.37% is expected in the next year compared to the current price of 30.42.
What is the GICS sector and industry of CUE stock?
CUE BIOPHARMA INC (CUE) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of CUE BIOPHARMA INC (CUE) based on its PE ratio?
CUE BIOPHARMA INC (CUE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).